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Alport syndrome, also termed hereditary nephritis, was initially
described in 1927 by A.C. Alport [1] as an inherited kidney disease
characterized by hematuria and sensorineural deafness. Later,
ocular lesions were also associated with the syndrome and, with
the introduction of the electron microscope, irregularities and
disruptions in the glomerular basement membrane (GBM) were
shown to be typical for this disorder as well [2, 31. The disease is
highly progressive and usually leads to renal failure during
adolescence or before middle age.
The disease is primarily inherited as an X-chromosome linked
dominant trait with an estimated gene frequency of 1:5,000 to
1:10,000, but autosomal forms also exist [2, 3]. The defective gene
in X-linked Alport syndrome was located in 1988 and 1989 to the
long arm of the X chromosome [4—61. In 1990, a gene encoding a
novel basement membrane (type IV) collagen a5 chain was
discovered and localized to the Alport gene region on chromo-
some X, and this was soon followed by identification of mutations
in this gene in Alport patients [7, 8]. More recently, mutations
have also been reported in the genes for the a3 and a4 type IV
collagen chains in the rarer autosomal forms of Alport syndrome
[9—11].
Presently, over 200 different mutations are identified in type IV
collagen genes in Alport patients, most of them in the COL4A5
gene that encodes the a6 chain of type IV collagen [12—16]. These
mutations can be considered responsible for abnormalities in the
structural framework of the GBM, with the result of kidney
manifestations. Identification of the genetic defects have opened
up the question if the disease can be treated by gene therapy. In
this article we discuss the potential for the development of gene
therapy of Alport syndrome in the light of current knowledge of
the pathomechanisms of the disease and our recent progress on
gene transfer into kidney and the molecular biology of type IV
collagen.
Clinical features of Alport syndrome
Patients with Alport syndrome usually have recurrent micro-
scopic or gross hematuria in childhood, earlier in males than in
females. Affected males, and in rare cases also females, usually
develop end-stage renal disease. The hearing loss, if present, is
sensorineural and primarily affects high tones. Electron micros-
copy usually reveals thinning and thickening of the GBM with
longitudinal splits into thin layers with a basket-weave pattern.
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These changes are most evident in male patients, except in boys of
very young age. Lenticonus, a peculiar change of lens shape, is
also frequently observed in Alport patients [2, 3]. The disease is
inherited and family history is present in 85% of cases. The
remaining 15% may represent new mutations [2]. A large propor-
tion of patients with renal failure and mutations in type IV
collagen do not have hearing loss or eye lesions [12—16]. Thus, the
classical clinical definition for the Alport syndrome, that is,
hereditary nephritis with hearing loss, does not apply to all
patients with type IV collagen defects. It is, therefore, important
that clinicians consider Alport syndrome as a possible diagnosis
for patients with hematuria and/or renal failure, even though they
do not have hearing deficiency, ocular lesions or family history.
Gregory et al [3] have recently described the criteria for diagnosis
of Alport syndrome (Table 1). According to their proposal, at
least four of the ten criteria must be satisfied to establish diagnosis
in an Alport syndrome family.
Molecular properties of the glomerular basement membrane
The filtration barrier of the kidney consists of the fenestrated
capillary endothelium, the GBM, and the epithelial podocytes
that are separated by the slit and connected by a thin diaphragm.
Similar to other basement membranes in the body, the GBM
consists of type IV collagen, laminin, proteoglycan and nidogen/
entactin [17]. Type IV collagen, the main structural component of
the GBM, forms a special type of quite flexible but tightly
crosslinked protein meshwork. The laminin molecules also form a
network that is linked to the type IV collagen network through
nidogen (entactin). The proteoglycan components are believed to
contribute to the filtration of macromolecules as an anionic
filtration barrier.
In Alport syndrome, the structure of the type IV collagen
network is substantially weakened due to mutations in isoforms of
this protein that are crucial for the GBM function. Knowledge
about the biosynthesis, structure and genetics of this protein is of
fundamental importance for consideration of experiments aimed
at gene therapy.
Type IV collagen: Genes, biosynthesis and tissue distribution
Type IV collagen is a basement membrane specific protein that
exists in several isoforms [17]. Similarly to other types of collagen,
the type IV collagen molecule is composed of three a chains that
contain numerous consecutive Gly-X-Y repeats, where proline
and hydroxyproline are frequently located in positions X and Y.
The presence of glycine as every third amino acid is essential, as
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Table 1. Criteria for the clinical diagnosis of Alport syndrome
according to Gregory et al [3]
1. Family history of nephritis of unexpected hematuria in a first
degree relative of the index case or in a male relative linked
through any numbers of females.
2. Persistent hcmaturia without evidence of another possibly inherited
nephropathy such as thin GBM disease, polycystic kidney
disease, or IgA nephropathy.
3. Bilateral sennsorineural hearing loss in the 2,000 to 8,000 Hz
range. The hearing loss develops gradually, is not present in
early infancy, and commonly presents before the age of 30 years.
4. A mutation in COL4An (where N 3, 4, or 5).
5. Immunohistochemical evidence of complete or partial lack of the
Alport epitope in glomerular, or epidermal basement
membranes, or both.
6. Widespread GBM ultrastructural abnormalities, in particular
thickening, thinning, and splitting.
7. Ocular lesions including anterior lenticonus, posterior subcapsular
cataract, posterior polymorphous dystrophy, and retinal flecks.
8. Gradual progression to ESRD in the index case of at least two
family members.
9. Macrothrombocytopenia or granulocytic inclusions.
10. Diffuse leiomyomatosis of esophagus or female genitalia, or both.
Four of the ten criteria should be fulfilled.
it is the only amino acid small enough to fit into the center of the
triple helix in collagenous proteins. The long collagenous struc-
ture in type IV collagen is interrupted by several non-collagenous
domains along the molecule. The interruptions are considered to
give flexibility to the molecule and facilitate the formation of a
network in basement membranes. In addition to the long collag-
enous domain, type IV collagen a-chains contain a noncollag-
enous domain, Nd, at the carboxyl end.
In the mammalian genome to date six different genes have been
found for type IV collagen. Each one of the COL4A1 - COL4A6
genes encodes a different a-chain, al-a6. The genes are located
pairwise in an unusual head-to-head fashion on chromosomes 2,
113 and X [17, 181. The six genes are likely to have evolved through
duplication and inversion of an ancestral gene with subsequent
two further rounds of duplication resulting in the three head-to-
head located gene pairs on different chromosomes. The type IV
collagen genes are large, over 100 kb, and complex, containing 46
to 52 exons [19—23].
Transcription of the a chain genes occurs as normally for
proteins, but during translation in the cisternae of the rough
endoplasmic reticulum the nascent a chains undergo several
enzymatic post-translational modifications (Fig. 1). These include
hydroxylation at the 4 and 3 positions of prolyl residues by
prolyl-4- and prolyl-3-hydroxylases, respectively, hydroxylation of
lysyl residues by lysylhydroxylase, and glycosylation of most hy-
droxylysyl residues by two glycosyl transferases to form glucosyl-
galactosyl-hydroxylysyl residues (a review on collagen biosynthesis
is in [241). Hydroxyproline is essential in collagen, where it is
required the maintenance of a stable triple helix through the
formation of hydrogen bonds between the a chains. In type IV
collagen about 60% of the prolyl residues are hydroxylated to
4-hydroxyproline and about 5% to 3-hydroxyproline, and about
90% of the lysyl residues are hydroxylated with about 90% of
them containing glucosyl-galactosyl disaccharides. The hydroxyly-
syl residues are believed to stabilize cross-links between mole-
cules, but the function of carbohydrates is unknown. In the
cisternae three chains assemble into a triple helix, after which the
post-translational modifications cease as the enzymes do not react
with a chains in a triple-helical protein. The triple-helical mono-
mers are then secreted out from the cell. Collagen a chains that
do not form a triple helix are degraded intracellularly.
Once secreted out from the cells, the triple-helical molecules
assemble by end-to-end aggregation and lateral alignment into a
tightly crosslinked network structure (Fig. 2). Two molecules bind
to each other through disulfide bonds at their carboxyl termini by
the association of the NC1 domains and four molecules assemble,
also via disulfide bridges, at the amino termini. Of the six
genetically distinct type IV collagen chains, the al and a2 chains
are ubiquitous in all basement membranes. In contrast, the a3, a4,
a5 and a6 chains are minor component chains with a more
restricted tissue distribution and thus probably specialized func-
tions. For example, molecules containing a3, a4 and a5 chains are
particularly abundant in the adult GBM [25], where they are
believed to form a3:a4:a5 heterotrimers. As yet, there is no direct
evidence that the a3, a4 and aS chains form the trimeric molecule
in the GBM, hut several studies have revealed that those chains
are co-expressed in the same tissues [26—291. At the protein
assembly level however, there are still several possibilities for how
the a3(IV), a4(IV), and a5(IV) chains are organized with respect
to: (a) each other forming triple-helical molecules that vary in
kind and composition of chains (relative abundance), and (b)
which triple-helical molecules, containing al(IV) to a6(IV)
chains, interact through Nd-Nd association forming a network.
Possibly, the a5(IV) chain forms triple-helical molecules separate
from the a3(IV) and a4(IV) chains, or it forms triple-helical
molecules together with the a3(IV) and a4(IV) chains. At the
suprastructure level, the chains appear to be distributed about at
least two networks: an al(IV)/a2(IV) network and an a3(IV)-
a5(IV), and, possibly, a6(IV) network. Clearly, the a5(IV) is
critical for the a3(IV) and a4(IV) incorporation and for the GBM
function, as revealed by the renal pathology caused by mutation in
the COL4A5 gene. Knowledge of the composition of the a-chains
and their organization in GBM is fundamental to the understand-
ing of the molecular basis for hereditary nephritis. In any case,
basement membranes composed of molecules containing the a3,
a4, and aS chains are believed to be stronger due to the presence
of high content of cysteine residues and, thus, disulfide crosslinks
[28, 29]. The strength of the structural network is considered to be
particularly important in basement membranes, such those of
renal glomeruli (GBM) and the lens capsule, which do not have
supportive collagen fibers. Therefore, mutations in the genes for
any of the three a chains of the main GBM type IV collagen
isoform are believed to result in the weak network and hematuria,
the main characteristic of Alport syndrome.
Molecular pathology of Alport syndrome
Alport syndrome is a type IV collagen disease. Mutations have
been described in the COL4A5 gene in over 200 cases [12—16], and
mutations have also been identified in the COL4A3 and COL4A4
genes in autosomal recessive forms of the disease [9, 11]. Inter-
estingly, there are several observations indicating that the a3(IV)
and a4(IV) chains are abnormal in the X-linked form of Alport
syndrome even though both are encoded by autosomal genes [26,
30, 31]. It is unclear how a mutation in the a5(IV) gene accounts
for the abnormalities in these other a(IV) chains, but it is possible
that one or more mechanisms that link the incorporation of
a3(IV), a4(IV), and a5(IV) chains could operate at the protein
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Fig. 1. Biosynthesis of type IV collagen in a cell
resting on a basement membrane follows the
pattern of that for collagenous proteins, in general
/24]. Following transcription and processing of
the primary transcript the mRNA is transported
to the cytosol to ribosomes where translation
occurs. Post-translational hydroxylations and
glycosylations take place on the nascent a
chains in the cisternae of the rough
endoplasmic reticulum. This is followed by
chain association, disulfide bonding and
formation of the triple helix of three
appropriate a chains. Single chains not
incorporated into triple helices are degraded,
while the triple-helical molecules are
transported through the Golgi apparatus to the
extracellular space where supramolecular
assembly occurs.
assembly and/or at the translational/transcriptional level [32]. At
the protein level, events at both triple helix formation and
supramolecular assembly need to be considered. For example, an
abnormal a5(IV) chain could lead to faulty heterotrimer assem-
bly, if the cs3(IV), cs4(IV), and a5(IV) chains are present in
heterotrimers, resulting in the absence of all these chains in GBM
of patients with X-linked Alport syndrome. Alternatively, the
cs3(IV) and a4(IV) chains may be in trimers distinct from those
containing the a5(IV) chain, the latter being necessary for the
incorporation of a3(IV) and a4(IV) chains containing trimers
into the supramolecular assembly of collagen type IV molecules.
Consequently, abnormality of a5(IV)-containing trimers in X-
linked Alport syndrome could lead to absence of the a3(IV)- and
a4(IV)-containirig trimers from the GBM. At the translational/
transcriptional level, expression of the a3(IV), a4(IV), or a5(IV)
chains might be coordinated, so the transcription or translation of
the a3(IV) chains might be impaired secondary to a mutation in
the cr5(IV) gene in the X-linked disease. The protein assembly
and the translational/transcriptional mechanisms need not be
mutually exclusive.
Almost all the mutations identified to date differ between
families. No clear correlation can be found between the nature of
a mutation and the respective phenotype. A small single amino
acid substitution can cause as severe symptoms as a large deletion
of almost the entire collagen gene. This, together with the
complexity of the collagen genes, makes DNA-based diagnosis of
Alport syndrome particularly difficult. About 15% of the muta-
tions characterized to date are large gene rearrangements, such as
deletions, insertions, inversions or duplications [12—16]. The rest
are small mutations, mainly single base changes, in addition to
small deletions, insertions or duplications. The mutations can
result in a complete absence of the protein (a-chain) in question,
a truncated protein or in a malfunctional protein. A loss of the
carboxyterminal noncollagenous domain would prohibit the for-
mation of heterotrimers. Several mutations in Alport syndrome
involve replacement of a glycine residue in the collagenous
domain by another amino acid. Glycine mutations are frequently
also the cause of other collagen disorders such as osteogenesis
imperfecta [33]. Based on the knowledge obtained from studies on
osteogenesis imperfecta, it has been suggested that the abnormally
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of a variety of hereditary diseases in the future. Although gene
therapy has not yet come of age as a real alternative for treatment
of human diseases, extensive research efforts are being made in
that direction. Alport syndrome, which primarily affects the renal
glomeruli, is an attractive disease target for gene therapy for the
following reasons. First of all, as it almost solely affects the kidney
glomeruli, extrarenal complications not being life-threatening or
occurring in all patients, the therapy can, at least initially, be
targeted to the kidney alone. Secondly, the kidney, with its well
separated circulatory system lends itself extremely well to organ
targeted gene transfer. Thirdly, the turnover of type IV collagen is
relatively slow, the half-life probably being over one year. How-
ever, extensive research still needs to be carried out before we can
expect to be able to do successful gene therapy of Alport
syndrome in humans, and there are numerous questions that need
to be answered before we know if gene therapy will become
possible for this disease. In the following we address some of the
key questions that researchers encounter today.
Fig. 2. Extracellular assembly of type IV collagen. Individual secreted
triple-helical molecules assemble by end-to-end associations into a net-
work-like structure into which other basement membrane proteins are
bound in a largely unknown fashion. In reality the type IV collagen
network structure also contains more complex laterally aligned molecules.
(Modified from [l71 used with permission).
folded triple helices are susceptible to degradative enzymes
leading to partial or total absence of all the a3, a4 and cx5 chains.
As a result, the structural framework of the GBM that requires
type IV molecules containing these polypeptide chains, becomes
structurally weak and disrupted.
Can Alport syndrome be treated by gene therapy?
To date, there is no satisfactory and curative conservative
treatment available for Alport syndrome [341. Patients developing
end-stage renal disease are treated by hemodialysis, and also by
kidney transplantation whenever possible. However, about 5% of
transplanted Alport males develop anti-GBM nephritis and lose
the allografted kidneys.
As a result of the advances in molecular genetic research, gene
therapy may be developing into a real possibility for the treatment
Is it possible to achieve effective gene transfer targeted to the
endothelial and epithelial cells of renal glomeruli?
The GBM is surrounded by endothelial and epithelial cells,
which both are believed to contribute to the biosynthesis of the
GBM type IV collagen. Due to lack of sensitivity, methods such as
in situ hybridization have not confirmed whether one or both cell
types contribute by the a3, cs4, and aS chains to the GBM.
However, from the gene transfer point of view, these cells can be
considered as the prime target.
Our recent work indicates that the targeting of genes to these
cells may not become a significant problem, even though previous
work with gene transfer into kidneys has been disappointing.
Intra-arterial injections of the viruses have yielded very low if any
gene delivery to glomerular cells [35, 36], but using liposomes,
together with sendai virus, transfer efficiency has been reported to
reach 15% of the glomeruli [37]. Recently using a kidney perfu-
sion method (Fig. 3), we could obtain up to 85% transfer efficacy
into pig glomeruli with an adenovirus vector containing the
f3-galactosidase reporter gene (Fig. 4) [38]. The key to this high
transfer efficacy is probably the prolonged contact time between
cells and viruses. The perfusion method is relatively easy to apply
to the kidney since it can be applied in situ, and may also prove
useful for the transfer of genes to other organs with well separated
blood supply.
Is it possible to obtain life-lasting and controlled expression of the
transferred gene?
This is a serious problem as it is the main hurdle of gene
therapy in general, and it poses one of the main challenges that
research in this field faces today. The adenovirus used in our
experiments provides, in its current form, expression for only six
to eight weeks, as it remains extrachromosomal and is not
integrated into the genome. Even though the half life of type IV
collagen is estimated to be over a year, this means that the
treatment would need to be periodically repeated during life with
Fig. 4. Immunolocalization of /3-galactosidase in a glomerulus. The protein can be observed mainly in podocytes while staining of endothelial and
mesangial cells is weaker and less frequent (immunoperoxidase, X700).
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Fig. 3. Scheme of the kidney perfusion system
used for gene transfer into pig kidneys /38]. The
closed-circuit system Consists of a reservoir for
the perfusate, a peristaltic pump, an oxygenator
and a thermostatic heater. The renal vein and
artery are cannulated and connected to the
Renal vein Clamp tubing perfusion system. The effluent from theureter is recovered into the reservoir. The 350
ml perfusate contains the recombinant virus
solution, porcine blood cells (17% hematocrit),
25,000 U heparin, 20,000 U penicillin and
contre 20,000 jsg streptomycin in Krebs-Ringer
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current methods, which would entail mean repeated surgical
operations. Retroviruses would theoretically be better, but they
cannot integrate large DNA inserts; also, they are only integrated
into replicating DNA, which is not the case for the glomerular
epithelial and endothelial cells that, for practical purposes, are
non-dividing cells. Therefore, successful future gene therapy of
Alport syndrome will depend on future developments in research
on gene transfer vectors.
Will a transferred type IV collagen cDNA or gene coupled to an
appropriate promoter be expressed in a controlled manner and
incorporated into normal GBM type IV collagen molecules?
We have already been able to express the full-length a5(IV)
collagen chain in cultured cells using plasmids, and are in the
process of doing similar studies with adenoviruses containing the
a5 eDNA. There is evidence that the incorporation of the a3, a4
and a5 chains into GBM is a coordinated event, with factors
acting at the transcriptional, translational and/or protein assembly
levels [32, 39]. The fact that the production of these three chains
is coordinated is probably a favorable thing. This means that the
limiting factor of intracellular synthesis of trimers (homo- or
hetero-) is likely to become the availability of the two other
cs-chains. Thus, if one chain is produced in excess, it will be
degraded intracellularly (see biosynthesis above). It has been
shown that al(IV) mRNA can exist 3- to 15-fold longer than
a2(IV) mRNA, even though the ratio of the chains in the protein
was 2:1, respectively [40]. Possibly any promoter can be used to
produce the cs5(IV) chain in excess. However, specific targeting or
the right level of expression may be achieved by using the
promoter of the a5(IV) chain gene. If the production of the
defective chain can be corrected to some extent, secretion of
normal molecules is likely to occur, even in the presence of some
abnormal malfunctional molecules. Female patients with X-linked
Alport's are obligate mosaics for a mutant COL4A5 gene and
provide a natural experiment for partial production of a normal
aS chain, which gene therapy would also attempt to create.
Female patients often have mild disease and avoid end-stage renal
disease, providing and encouraging observation that total replace-
ment of mutant with normal a5-chains would not be necessary in
any gene therapy treatment designed. However, only experimen-
tal work will prove or disprove of these speculations.
Can corrected type IV collagen trimers be incorporated into the
GBM and restore its structure and function?
This is still an open question which will have to be addressed
experimentally in animal models. Our work in the Samoyed dog
model of X-linked hereditary nephritis (see below) has shown that
carrier female dogs, in which glomeruli are chimeric for the
COL4A5 mutation, have a mixture of abnormal and normal GBM
in early stages of the disease. Later in life, however, the GBM
begins to take on a more normal appearance throughout all
glomeruli [41]. One explanation for this observation is that normal
molecules can spread within the GBM to restore the structure.
Thus, incorporation of type IV collagen trimers into the GBM
may occur with restoration of its structure and function, thereby
eliminating a major obstacle for gene therapy of Alport's disease.
Are there appropriate animal models for gene therapy studies on
Alport syndrome?
An animal model for a human disease is essential for testing the
feasibility of gene therapy of diseases in humans. From the Alport
syndrome point of view, the situation is quite favorable as models
for both the X-linked and autosomal forms have been described in
dogs. For example, a model for the X-linked disease has been
described in Samoyed dogs [42, 43]. Hemizygous male dogs
develop hematuria at the age of three months and end-stage renal
disease usually at nine months of age. The disease is caused by a
nonsense mutation in the X chromosomal COL4A5 gene and is
both clinically and morphologically similar to that in humans [43].
Such dogs may prove excellent models for gene therapy experi-
ments.
Conclusion
As a treatment, somatic gene therapy is a new type of treatment
aiming directly at the causative defect, not only at the symptoms.
Gene therapy has not really come of age yet, but extensive efforts
are being made in numerous laboratories to explore the realistic
possibilities for this new treatment. In spite of many hurdles, there
is still cautious optimism among researchers about the possibili-
ties for developing lasting gene therapy protocols for several
inherited disorder.
Identification of the genes affected in Alport syndrome has
raised questions about the possibilities for gene therapy, and in
this article we have discussed the potentials for the development
of such therapy for Alport syndrome. Based on the knowledge we
have about the type IV collagen chains affected in the disease, we
consider it possible both theoretically and practically to correct, at
least transiently, the abnormal GBM type IV collagen network by
transfer of a normal a(IV) gene into cells that synthesize the
protein in vivo. We have been able to transfer reporter genes with
high efficiency into glomerular cells in vivo by kidney perfusion,
and will soon be able to explore if the defect can actually be
corrected in dogs with Alport syndrome. If those experiments
yield promising results, gene therapy of human Alport patients
may become a possibility some day. However, future gene therapy
of this disease, as for any disease for that matter, will depend
largely on the development of better gene transfer vectors, and on
more knowledge about the pathophysiology of the disease and
regulation of the genes to be treated.
Reprint requests to Karl Tiyggvason, M.D., Ph.D., Department of Medical
Biochemistiy and Biophysics, Karolinska Institute, S-171 77 Stockholm,
Sweden.
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